Jaclyn Neely
Impact in
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
Papers in
- Oncology 41
- Cancer Immunotherapy and Biomarkers 38
- Colorectal Cancer Treatments and Studies 10
- Pancreatic and Hepatic Oncology Research 5
- Hepatology 26
- Hepatocellular Carcinoma Treatment and Prognosis 26
- Co-authors
- Bruno Sangro (30 shared papers)Thomas Yau (18 shared papers)Ignacio Melero (24 shared papers)Anthony B. El-Khoueiry (21 shared papers)Masatoshi Kudo (19 shared papers)Su Pin Choo (17 shared papers)Ann‐Lii Cheng (8 shared papers)Richard S. Finn (8 shared papers)
- Journals
- Journal of Clinical Oncology (17 papers)Annals of Oncology (8 papers)Journal of Hepatology (6 papers)Cancer Research (3 papers)Journal for ImmunoTherapy of Cancer (2 papers)
- Partner nations
- United StatesSpainJapan
In The Last Decade
Jaclyn Neely
41 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 66
- Hepatology 1.2k
- Oncology 1.3k
- Immunology 587
- Pathology and Forensic Medicine 417
- Cancer Research 231
Countries citing papers authored by Jaclyn Neely
This map shows the geographic impact of Jaclyn Neely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaclyn Neely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaclyn Neely more than expected).
Fields of papers citing papers by Jaclyn Neely
This network shows the impact of papers produced by Jaclyn Neely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaclyn Neely. The network helps show where Jaclyn Neely may publish in the future.
Co-authors
The 25 scholars most cited alongside Jaclyn Neely, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Hit paper breakdown → | 2019 | 497 |
| 2 | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody Hit paper breakdown → | 2016 | 281 |
| 3 | Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma Hit paper breakdown → | 2020 | 274 |
| 4 | 2019 | 178 | |
| 5 | CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis Hit paper breakdown → | 2021 | 141 |
| 6 | 2020 | 93 | |
| 7 | 2019 | 79 | |
| 8 | 2017 | 68 | |
| 9 | 2020 | 53 | |
| 10 | 2016 | 49 | |
| 11 | 2022 | 46 | |
| 12 | 2020 | 42 | |
| 13 | 2016 | 31 | |
| 14 | 2023 | 27 | |
| 15 | 2020 | 25 | |
| 16 | 2016 | 24 | |
| 17 | 2017 | 21 | |
| 18 | 2024 | 18 | |
| 19 | 2021 | 17 | |
| 20 | Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040 | 2017 | 12 |
About Jaclyn Neely
Jaclyn Neely is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Cancer Research, having authored 42 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (38 papers), Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Ferroptosis and cancer prognosis (12 papers), Colorectal Cancer Treatments and Studies (10 papers), Pancreatic and Hepatic Oncology Research (5 papers), Lung Cancer Treatments and Mutations (4 papers), Cancer Genomics and Diagnostics (3 papers) and Cancer Mechanisms and Therapy (3 papers). The work is most often cited by research in Hepatology (1.2k citations), Oncology (1.3k citations), Immunology (587 citations), Pathology and Forensic Medicine (417 citations) and Cancer Research (231 citations). Jaclyn Neely has collaborated with scholars based in United States, Spain and Japan. Frequent co-authors include Bruno Sangro, Thomas Yau, Ignacio Melero, Anthony B. El-Khoueiry, Masatoshi Kudo, Su Pin Choo, Ann‐Lii Cheng, Richard S. Finn, Yun Shen and Marina Tschaika. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Hepatology, Cancer Research and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.